A Parallel-group, Randomized, Open-label Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D.
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- compound response
研究概览
简要总结
The goal of this clinical trial is to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D. Patients with compensated CHD who satisfy the eligibility criteria are stratified by the presence or absence of liver cirrhosis and randomized into three groups at a 1:1:1 ratio. The subjects will receive continuous L47 (2.1 mg/d and 4.2 mg/d, s.c.) treatment for 48 weeks (groups A and B), or delayed treatment for 48 weeks (group C). Primary endpoint evaluation will be performed after the subjects complete the 48-week treatment.
详细描述
This is a three-arm, parallel-group, randomized, open-label, delayed-controlled phase IIb clinical trial. The study flow chart is shown in Fig. 1.2.1. CHD patients with compensated liver function who satisfy the eligibility criteria are stratified by the presence or absence of liver cirrhosis and randomized into the 2.1 mg group, 4.2 mg group, and delayed treatment group at a 1:1:1 ratio (Table 1.1). The subjects will receive continuous L47 (2.1 mg/d and 4.2 mg/d, s.c.) treatment for 48 weeks (groups A and B), or delayed treatment for 48 weeks (group C). The 1st interim analysis will be performed when all subjects complete the Week12 visit to determine the optimal dose for the extended treatment period following the trial. The 2nd interim analysis will be performed when all subjects complete the Week24 visit. Upon completion of the 48th week of treatment, the primary endpoint was assessed, and the trial was officially concluded.
After the conclusion of the trial, all subjects in each group entered the extension treatment period and were all treated continuously with the L47 optimal dose for 96 weeks. After the extension treatment ended, all groups discontinued the medication and were observed for 48 weeks follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Male or female subjects aged 18-65 years (both inclusive);
- •2. Subjects with positive HBsAg and/or HBV DNA for at least 6 months ("CHB");
- •3. Subjects with positive serum anti-HDV antibody before or at screening or with positive HDV RNA for at least 6 months before screening ("CHD");
- •4. Subjects with positive and quantifiable HDV RNA before enrollment;
- •5. 1 × ULN < ALT < 10 × ULN;
- •6. Subjects who should be treated with nucleoside/nucleotide reverse transcriptase inhibitors at enrollment or after enrollment according to the guidelines for the treatment of hepatitis D (compensated cirrhosis with detectable HBV DNA, or HBV DNA > 2000 IU/mL in patients without cirrhosis) and consent to the use of entecavir for the treatment of chronic hepatitis B;
- •7. Subjects who do not plan a pregnancy within 3 years (women who are not pregnant or lactating, and males who agree to take effective contraceptive measures throughout the treatment period and for 3 months after the last dose);
- •8. Subjects exhibiting good compliance to the study protocol;
- •9. Subjects who understand the ICF and agree to sign it.
排除标准
- •1. Subjects suffering from severe decompensated liver fibrosis or decompensated liver cirrhosis with a Child-Pugh score > 7;
- •2. Decompensated liver disease: Direct bilirubin > 1.2 x ULN or prothrombin time > 1.2 x ULN or serum albumin < 35 g/L;
- •3. Abnormal hematology findings: White blood cell count (WBC) < 3 × 109/L, neutrophil count < 1.5 × 109/L or platelet count < 60 × 109/L;
- •4. Creatinine clearance < 60 mL/min;
- •5. Subjects who have any of the following conditions:
- •History of current or past decompensated liver diseases (including coagulopathy, hepatic encephalopathy, and variceal bleeding);
- •Comorbidity of underlying diseases such as severe infection, heart failure and chronic obstructive pulmonary disease, and other severe diseases;
- •Diabetes mellitus and hypertension not effectively controlled (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg);
- •Current or previous uncontrolled epilepsy or psychiatric disorders;
- •History of solid organ transplantation;
- •Evidence of active or suspected malignancies or history of malignancies, or untreated premalignant lesions within the past 5 years (except for successfully treated cervical carcinoma in situ at least 1 year before screening, and successfully treated basal cell carcinoma and squamous cell carcinoma [≤ 3 cases of resected skin cancer within 5 years before screening ]), or history of liver cancer;
- •History of alcohol abuse or drug addiction at present or within 6 months prior to participation in this study;
- •Subjects co-infected with hepatitis A, C, or E virus or with uncontrolled HIV co-infection (those with positive HCV antibody but negative HCV RNA at screening are eligible for enrollment. HIV-infected patients may be enrolled if cluster of differentiation 4 (CD4) cell count is > 500/mL and HIV RNA is below the limit of detection for at least 12 months);
- •7. Presence of one or more other known primary or secondary liver diseases, such as alcoholism, autoimmune hepatitis, malignancies involving the liver, hemochromatosis, other congenital or metabolic diseases affecting the liver, congestive heart failure, or other serious cardiopulmonary diseases, excluding hepatitis B;
- •8. Subjects with one or more autoimmune diseases, immune-related extrahepatic manifestations (such as vasculitis, purpura, arteritis nodosa, peripheral neuropathy, and glomerulonephritis), or a history of requiring regular use of systemic corticosteroids (inhaled corticosteroids are allowed) or other immunosuppressive agents;
- •9. Subjects who have used interferon within 6 months before screening;
- •10. Subjects who have used L47 or Bulevirtide within 3 months;
- •11. Allergy to entecavir;
- •12. Pregnant or breastfeeding women;
- •13. Subjects who participated in other drug clinical trials within 30 days before randomization;
- •14. Subjects who are receiving prohibited treatment at screening that cannot be discontinued;
- •15. Subjects who cannot comply with the study protocol and complete all procedures as scheduled, or have significant abnormalities in other laboratory or auxiliary examinations, which render them ineligible for this trial.
研究组 & 干预措施
Hepalatide 2.1mg
hepalatide 2.1mg/d, s.c. for 48 weeks
干预措施: hepalatide (Drug)
Hepalatide 4.2mg
hepalatide 4.2mg/d, s.c. for 48 weeks
干预措施: hepalatide (Drug)
结局指标
主要结局
compound response
时间窗: Week 48
Decrease in HDV RNV by ≥ 2 log10 from baseline and ALT normalization
次要结局
- HDV RNA below LLOQ(Week 48)
- The incidence rate of Liver-related endpoint events.(Week 240)
- Decrease in HDV RNA by ≥ 2 log10 from baseline or undetectable HDV RNA(Week 48)
- Decrease in HDV RNA from baseline(Week 48)
- Decrease in ALT from baseline(Week 48)
- Change in fibrosis 4 (FIB-4) index from baseline(Week 48)
- Change in Model for End-Stage Liver Disease (MELD) score from baseline(Week 48)
- ALT normalization(Week 48)
- Changes in subjects' METAVIR system scores from baseline.(Week 48)
- Change in Child-Pugh score from baseline(Week 48)